On Monday I looked at three ASX shares that have been given buy ratings by leading brokers this week.
Unfortunately, not all shares are in favour with brokers right now. The three shares listed below have all just been given sell ratings. Here’s why they are bearish on them:
Commonwealth Bank of Australia (ASX: CBA)
According to a note out of Credit Suisse, its analysts have downgraded this banking giant’s shares to an underperform rating with a $77.60 price target. The broker made the move largely on valuation grounds, noting that its shares are trading a lot higher than its current price target. In addition to this, it has downgraded its earnings in response to higher than expected insurance claims. The Commonwealth Bank share price is down slightly at $84.44 on Tuesday.
IOOF Holdings Limited (ASX: IFL)
Analysts at UBS have retained their sell rating and cut the price target on this financial services company’s shares slightly to $6.80. According to the note, IOOF’s first half update was weaker than the broker was expecting. And whilst it acknowledges that FY 2020’s financial results were going to be messy due to acquisitions and divestments, its core earnings are notably lower than its estimates. The IOOF share price has dropped 2% to $7.55 on Tuesday afternoon.
ResMed Inc. (ASX: RMD)
A note out of the Macquarie equities desk reveals that its analysts have held firm with their underperform rating and $17.00 price target on this sleep treatment specialist’s shares. According to the note, although ResMed delivered a second quarter result that was a touch ahead of its expectations, it wasn’t enough to change its view. The broker remains concerned with risks relating to reimbursement rates and regulatory changes. It also notes that competition is increasing in the industry. The ResMed share price is changing hands at $24.61 this afternoon.
Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading over 40% off it's high, all while offering a fully franked dividend yield over 3%...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.